Impact of catheter arteriography on the serum level of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase

CardioVascular and Interventional Radiology

Volumn 31, Issue 3, 2008, Pages 490-495

  Bozlar, Ugur ^a   Ugurel, Mehmet Sahin ^a   Ozcan, Omer ^a   Cakir, Erdinc ^a   Ustunsoz, Bahri ^a   Ucoz, Taner ^a   Bilgi, Cumhur ^a   Somuncu, Ibrahim ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Arteriography; Asymmetric dimethylarginine (ADMA); Contrast media; Nitric oxide; Vascular

Indexed keywords

IODINATED CONTRAST MEDIUM; IOHEXOL; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR;

ADULT; AGE; AGED; ARTERIOGRAPHY; ARTICLE; BRAIN ANGIOGRAPHY; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; AGED; ANGIOGRAPHY; ARGININE; BIOLOGICAL MARKERS; CATHETERIZATION, PERIPHERAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE; PROBABILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC;

EID: 43249109031     PISSN: 01741551     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00270-008-9312-x     Document Type: Article

References (37)

1. Kielstein JT, Impraim B, Simmel S et al (2004) Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 109(2):172-177
2. Cooke JP, Dzau VJ (1997) Nitric oxide synthase:role in the genesis of vascular disease. Annu Rev Med 48:489-509
3. Boger RH (2003) The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 59(4):824-833
4. Moncada S, Higgs A (1993) The L-arginine-nitric oxide pathway. N Engl J Med 329(27):2002-2012
5. McCarty MF (2004) Vascular endothelium is the organ chiefly responsible for the catabolism of plasma asymmetric dimethylarginine-an explanation for the elevation of plasma ADMA in disorders characterized by endothelial dysfunction. Med Hypoth 63(4):699-708
6. Dayoub H, Achan V, Adimoolam S et al (2003) Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 108(24):3042-3047
7. Böger RH (2004) Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor. J Nutr 134(Suppl 10):2842S-2847S
8. Baylis C (2006) Nitric oxide deficiency in chronic renal disease. Eur J Clin Pharmacol 62(Suppl):123-130
9. Tran CT, Leiper JM, Vallance P (2003) The DDAH/ADMA/NOS pathway. Atheroscler Suppl 4(4):33-40
10. Valkonen VP, Paiva H, Salonen JT et al (2001) Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358(9299):2127-2128
11. Surdacki A, Nowicki M, Sandmann J et al (1999) Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 33(4):652-658
12. Böger RH, Bode-Böger SM, Thiele W et al (1997) Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 95(8):2068-2074
13. Böger RH, Bode-Böger SM, Szuba A et al (1998) Asymmetric dimethylarginine (ADMA) a novel risk factor for endothelial dysfunction its role in hypercholesterolemia. Circulation 98(18):1842-1847
14. Sydow K, Schwedhelm E, Arakawa N et al (2003) ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of l-arginine and B vitamins. Cardiovasc Res 57(1):244-252
15. Usui M, Matsuoka H, Miyazaki H et al (1998) Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 62(26):2425-2430
16. Yoo JH, Lee SC (2001) Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 158(2):425-430
17. Gorenflo M, Zheng C, Werle E et al (2001) Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol 37(4):489-492
18. Kielstein JT, Böger RH, Bode-Böger SM et al (1999) Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 10(3):594-600
19. Saitoh M, Osanai T, Kamada T et al (2003) High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure:role in reduction of plasma nitric oxide level. Heart Vessels 18(4):177-182
20. Fard A, Tuck CH, Donis JA et al (2000) Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 20(9):2039-2044
21. Bae SW, Stuhlinger MC, Yoo HS et al (2005) Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am J Cardiol 95(6):729-733
22. Steinberg HO, Paradisi G, Hook G et al (2000) Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes 49(7):1231-1238
23. Azuma H, Sato J, Hamasaki H et al (1995) Accumulation of endogenous inhibitors for nitric oxide synthesis and decreased content of L-arginine in regenerated endothelial cells. Br J Pharmacol 115(6):1001-1004
24. Boger RH, Sydow K, Borlak J et al (2000) LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 87(2):99-105
25. Osanai T, Saitoh M, Sasaki S et al (2003) Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension 42(5):985-990
26. Chen BM, Xia LW, Zhao RQ (1997) Determination of NG, NG-dimethylarginine in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 692(2):467-471
27. Lancaster JR Jr (1994) Simulation of the diffusion and reaction of endogenously produced nitric oxide. Proc Natl Acad Sci USA 91(17):8137-8141
28. Balbatun A, Louka FR, Malinski T (2003) Dynamics of nitric oxide release in the cardiovascular system. Acta Biochim Pol 50(1):61-68
29. Wykretowicz A, Dziarmaga M, Szczepanik A et al (2003) Prospective evaluation of hydroperoxide plasma levels and stable nitric oxide end products in patients subjected to angioplasty for coronary artery disease. Int J Cardiol 89(2-3):173-178
30. Clowes AW, Clowes MM, Fingerle J et al (1989) Kinetics of cellular proliferation after arterial injury. V. Role of acute distension in the induction of smooth muscle proliferation. Lab Invest 60(3):360-364
31. Iwashina M, Shichiri M, Marumo F et al (1998) Transfection of inducible nitric oxide synthase gene causes apoptosis in vascular smooth muscle cells. Circulation 98(12):1212-1218
32. Janero DR, Ewing JF (2000) Nitric oxide and postangioplasty restenosis: pathological correlates and therapeutic potential. Free Radic Biol Med 29(12):1199-1221
33. Yao S, Ober JC, Krishnaswami A et al (1992) Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. Circulation 86(4):1302-1309
34. Hutcheson IR, Griffith TM, Pitman MR et al (1999) Iodinated radiographic contrast media inhibit shear stress- and agonist-evoked release of NO by the endothelium. Br J Pharmacol 128(2):451-457
35. Furuta W, Yamauchi A, Dohgu S et al (2002) Contrast media increase vascular endothelial permeability by inhibiting nitric-oxide production. Invest Radiol 37(1):13-19
36. Zhang H, Holt CM, Malik N et al (2000) Effects of radiographic contrast media on proliferation and apoptosis of human vascular endothelial cells. Br J Radiol 73(874):1034-1041
37. Baile EM, Pare PD, D'yachkova Y et al (1999) Effect of contrast media on coronary vascular resistance: contrast-induced coronary vasodilatation. Chest 116(4):1039-1045